Shares of Grace Therapeutics (GRCE) are down $2.07, or 48%, to $2.24 after the FDA issued a Complete Response Letter for the company’s New Drug Application for GTx-104 for the treatment of patients with aSAH.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRCE: